LE, B., M, K., SE, A., JC, C., N, G., TA, O., . . . M, W. (2026). Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: A phase 2 study. Blood. https://doi.org/10.1182/blood.2025032422
Chicago Style (17th ed.) CitationLE, Budde, et al. "Mosunetuzumab Plus Polatuzumab Vedotin in Relapsed/refractory MCL After BTK Inhibitor Therapy: A Phase 2 Study." Blood 2026. https://doi.org/10.1182/blood.2025032422.
MLA (9th ed.) CitationLE, Budde, et al. "Mosunetuzumab Plus Polatuzumab Vedotin in Relapsed/refractory MCL After BTK Inhibitor Therapy: A Phase 2 Study." Blood, 2026, https://doi.org/10.1182/blood.2025032422.
Warning: These citations may not always be 100% accurate.
